Evidence map›Paper›PMID 40634519›Full record

ArticleScientific reports2025

Concordance of HER2-low scoring in breast carcinomas among pathologists.

Snježana Tomić, Tatjana Kapicl Ivković, Marija Milković Periša, Duško Đunđerović, Maja Jovičić Milentijević, Svetlana Oprić, Slobodanka Mitrović, Irena Jovanić, Savelina Popovska, Svitlana Bachurska and 11 more

Erratum issuedAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

21 authors.

Snježana TomićDepartment of Pathology and Cytology, University Hospital Centre Split, Split, Croatia.
Tatjana Kapicl IvkovićMedical Faculty University of Novi Sad, Novi Sad, Serbia.
Marija Milković PerišaDepartment of Pathology and Cytology, University Hospital Centre Zagreb, Zagreb, Croatia.
Duško ĐunđerovićInstitute of Pathology, Faculty of Medicine, University of Belgrade, Belgrade, Serbia.
Maja Jovičić MilentijevićMedical Faculty, University of Niš, Niš, Serbia.
Svetlana OprićUniversity Hospital Medical Centre Bežanijska kosa, Belgrade, Serbia.
Slobodanka MitrovićDepartment of Pathology, Faculty of Medical Sciences, University of Kragujevac, Kragujevac, Serbia.
Irena JovanićDepartment of Pathology, Institute of Oncology and Radiology of Serbia, Belgrade, Serbia.
Savelina PopovskaMedical University Pleven, Pleven, Bulgaria.
Svitlana BachurskaDepartment of General and Clinical Pathology, USBALO, Sofia, Bulgaria.
Desislava TashkovaDepartment of Pathology, Complex Oncology Center, Plovdiv, Bulgaria.
Kalin KalchevSveta Marina University Hospital, Varna, Bulgaria.
Ljiljana VučkovićFaculty of Medicine, University of Montenegro, Podgorica, Montenegro.
Manuela AvirovićDepartment of Pathology, University Hospital of Rijeka, Rijeka, Croatia.
Emina BabarovićDepartment of Pathology, University Hospital of Rijeka, Rijeka, Croatia.
Melita Perić BaljaDepartment of Pathology, Clinical Hospital Sister of Mercy, Zagreb, Croatia.
Čedna Tomasović-LončarićDepartment of Pathology, University Hospital Dubrava, Zagreb, Croatia.
Jasmina RajcDepartment of Pathology and Forensic Medicine, Osijek University Hospital, Osijek, Croatia.
Irena ZagoracDepartment of Pathology and Forensic Medicine, Osijek University Hospital, Osijek, Croatia.
Davor OršolićLaboratory for Machine Learning and Knowledge Representation, Ruđer Bošković Institute, Zagreb, Croatia.
Toni ČeprnjaDepartment of Pathology and Cytology, University Hospital Centre Split, Split, Croatia. toni.ceprnja@mefst.hr.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The results from DESTINY-Breast 04 and the subsequent introduction of trastuzumab-deruxtecan as a potential treatement for HER2-low breast cancer necessitated the reevaluation of HER2 scoring. The discordance in HER2 scoring reported in previous studies led us to initiate a regional ring study and to assess our data. This ring study involved 61 breast pathology experts from four countries across the Balkans region. The research comprised 20 samples, including biopsies and surgical specimens, sourced from the archives of one institution. We amassed a total of 1220 scores. The findings indicate a significant degree of interobserver agreement among pathologists in scoring individual categories (scores 0, 1+, 2+, and 3+), with even higher agreement observed when scores 1 + and 2 + were combined into a single, HER2-low category. The findings of this study indicate that adequate education, awareness regarding the therapeutic significance of the HER2-low category, and expertise in breast pathology facilitate the accurate identification of HER2-low breast cancers. These findings will promote ongoing training in breast pathology within the region and will provide a reference for subsequent research efforts.

Indexed as

Breast NeoplasmsErb-b2 Receptor Tyrosine KinasesPathologistsFemaleHumansObserver VariationTrastuzumabERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesTrastuzumabBreast cancerHER2-lowTrastuzumab-deruxtecan

Identifiers

PMID40634519
PMCPMC12241539

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.